DOI: https://doi.org/10.7705/biomedica.v36i3.3183

Inmunoterapia con alérgenos: mecanismos de acción, impacto terapéutico y socioeconómico. Consenso de la Asociación Colombiana de Alergias, Asma e Inmunología

Jorge Sánchez, Ricardo Cardona, Luis Caraballo, Carlos Serrano, Ruth Ramírez, Susana Díez, Elizabeth García, Ana María Segura, Alfonso Cepeda, María Minotas

Resumen


Las alergias constituyen un conjunto de enfermedades de gran prevalencia. Cuando los procesos alérgicos no se controlan, pueden poner en peligro la salud e, incluso, la vida de los pacientes y, además, su efecto económico y social es considerable. El objetivo de esta revisión es presentar un consenso práctico de la información científica disponible sobre el empleo de la inmunoterapia en las enfermedades alérgicas con la colaboración de varios institutos y universidades de Colombia, por solicitud de la Asociación Colombiana de Alergia, Asma e Inmunología. La revisión incluyó aspectos prácticos presentados desde el punto de vista de médicos generales, alergólogos, inmunólogos, internistas y pediatras con experiencia en el campo de las alergias. Con base en la evidencia científica actual a nivel nacional e internacional, se describió de forma detallada en qué consiste la inmunoterapia, sus indicaciones, contraindicaciones y sus beneficios para la salud, así como en el ámbito socioeconómico. Se concluyó que la inmunoterapia es efectiva y segura, y que, además, puede reducir sustancialmente el costo del tratamiento global de los pacientes alérgicos.


Palabras clave


alérgenos; consenso; asma; anafilaxia; dermatitis; conjuntivitis; himenópteros; inmunoterapia; rinitis

Texto completo:

PDF HTML

Referencias


1. Sawicki GS, Vilk Y, Schatz M, Kleinman K, Abrams A, Madden J. Uncontrolled asthma in a commercially insured population from 2002 to 2007: Trends, predictors, and costs. J Asthma. 2010;47:574-80. http://dx.doi.org/10. 3109/ 02770901003792841
2. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186. http://dx.doi.org/10.1002/14651858.CD001186.pub2
3. Bousquet J, Lockey R, Malling HJ. Allergen immuno-therapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558-62. http://dx. doi.org/10.1016/S0091-6749(98)70271-4
4. Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy Organization anaphylaxis guidelines: Summary. J Allergy Clin Immunol. 2011;127:587-93.e1-22. http://dx.doi.org/10.1016/j.jaci.2011.01.038
5. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy. 2011;66:725-32. http://dx. doi.org/10.1111/j.1398-9995.2011.02589.x
6. Scadding G, Durham SR. Mechanisms of sublingual immu-notherapy. Immunol Allergy Clin North Am. 2011;31:191-209. http://dx.doi.org/10.1016/j.iac.2011.02.005
7. Fernández-Caldas E, Baena-Cagnani CE, López M, Patiño C, Neffen HE, Sánchez-Medina M, et al. Cutaneous sensitivity to six mite species in asthmatic patients from five Latin American countries. J Investig Allergol Clin Immunol. 1993;3:245-9.
8. Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: A cross-sectional study. BMC Pulm Med. 2012;12:17. http://dx.doi.org/10.1186/1471-2466-12-17
9. Sánchez J, Díez S, Cardona R. Sensibilización a aeroaler-genos en pacientes alérgicos de Medellín, Colombia. Rev Alerg Mex. 2012;59:139-47.
10. van Strien RT, Koopman LP, Kerkhof M, Spithoven J, de Jongste JC, Gerritsen J, et al. Mite and pet allergen levels in homes of children born to allergic and nonallergic parents: The PIAMA study. Environ Health Perspect. 2002;110:A693-8.
11. Caudri D, Wijga AH, Smit HA, Koppelman GH, Kerkhof M, Hoekstra MO, et al. Asthma symptoms and medication in the PIAMA birth cohort: Evidence for under and overtreat-ment. Pediatr Allergy Immunol. 2011;22:652-9. http://dx.doi.org/10.1111/j.1399-3038.2011.01193.x
12. Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhino-conjunctivitis. BMC Med. 2014;12:71. http://dx.doi.org/10. 1186/1741-7015-12-71
13. Yepes-Núñez JJ, Gómez C, Espinoza Y, Cardona R. Impacto de la inmunoterapia subcutánea con Dermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma alérgica. Biomédica. 2014;34:282-90. http://dx.doi.org/10.7705/biomedica.v34i2. 1744
14. Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251-6. http://dx.doi.org/10.1067/mai.2002.121317
15. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943-8. http://dx.doi.org/10.1111/j.1398-9995.2007.01451.x
16. Sánchez J, Restrepo M, Díez S, Cardona R. Comparación del efecto clínico de la inmunoterapia en pacientes con asma alérgica según la edad y el patrón de sensibilización. Alerg Asma Inmunol Pediatr. 2012;21:77-85.
17. Burks AW, Calderón MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288-96.e3. http://dx.doi.org/10.1016/j.jaci.2013.01.049
18. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18-27. http://dx.doi.org/10.1016/j.jaci.2010.11.030
19. Taylor A, Akdis M, Joss A, Akkoç T, Wenig R, Colonna M, et al. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol. 2007;120:76-83. http://dx.doi.org/10.1016/j.jaci.2007.04.004
20. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. http://dx.doi.org/10.1146/annurev.immunol.19.1.683
21. Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol. 2004;173:6526-31. http://dx.doi.org/10.4049/jimmunol.173.11.6526
22. Radulovic S, Wilson D, Calderón M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66:740-52. http://dx.doi.org/10.1111/j.1398-9995.2011.02583.x
23. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008;63:1455-63. http://dx.doi.org/10.1111/j.1398-9995.2008.01774.x
24. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol. 1999;103:326-32.
25. Sánchez J, Cardona R. Effect of immunotherapy on basophil activation induced by allergens in patients with atopic dermatitis. Rev Alerg Mex. 2014;61:168-77.
26. Hitomi K, Tahara-Hanaoka S, Someya S, Fujiki A, Tada H, Sugiyama T, et al. An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. Nat Immunol. 2010;11:601-7. http://dx.doi.org/10.1038/ni.1886
27. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771-81. http://dx.doi.org/10.1016/j.immuni.2008.08.018
28. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133:621-31. http://dx.doi.org/10.1016/j.jaci.2013.12.1088
29. Vergara C, Caraballo L. Asthma mortality in Columbia. Ann Allergy Asthma Immunol. 1998;80:55-60.
30. Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol. 2011;127:44-5. http://dx.doi.org/10. 1016/j.jaci.2010.09.037
31. Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma control in Latin America: The Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Pública. 2005;17:191-7. http://dx.doi.org/10.1590/S1020-49892005000300007
32. Neffen H, Baena-Cagnani CE, Malka S, Sole D, Sepúlveda R, Caraballo L, et al. Asthma mortality in Latin America. J Investig Allergol Clin Immunol. 1997;7:249-53.
33. Abramson MJ, Puy RM, Weiner JM. Is allergen immuno-therapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969-74. http://dx.doi.org/10.1164/ajrccm/151.4.969
34. Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: Allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8:1-9. http://dx.doi.org/10.1097/ACI.0b013e3282f3f42f
35. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:319-25. http://dx.doi.org/10.1016/j.jaci.2005.11.014
36. Radulovic S, Calderón MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893. http://dx.doi.org/10.1002/14651858.CD002893
37. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5Suppl.):S147-334.
38. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008*. Allergy. 2008;63 (Suppl.86):8-160. http://dx.doi.org/10.1111/j.1398-9995.2007.01620.x
39. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466-76. http://dx.doi.org/10.1016/j.jaci.2010.06.047
40. Ciprandi G, Incorvaia C, Dell’Albani I, Masieri S, Cavaliere C, Puccinelli P, et al. Characteristics of candidates for allergen immunotherapy. Allergy Rhinol (Providence). 2013;4:e77-81. http://dx.doi.org/10.2500/ar.2013.4.0061
41. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130:1049-62. http://dx.doi.org/10.1016/j.jaci.2012.07.053
42. Calderón MA, Frankland AW, Demoly P. Allergen immunotherapy and allergic rhinitis: False beliefs. BMC Med. 2013;11:255. http://dx.doi.org/10.1186/1741-7015-11-255
43. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical Practice Guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1Suppl.): S1-43. http://dx.doi.org/10.1177/0194599814561600
44. Feng S, Xu Y, Ma R, Sun Y, Luo X, Li H. Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: A systematic review and meta-analysis. PLoS One. 2014;9:e86529. http://dx.doi.org/10.1371/journal.pone.0086529
45. Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy. 2011;67: 321-7. http://dx.doi.org/10.1111/j.1398-9995.2011.02759.x
46. Durham SR, Birk AO, Andersen JS. Days with severe symptoms: An additional efficacy endpoint in immunotherapy trials. Allergy. 2010;66:120-3. http://dx.doi.org/10.1111/j. 1398-9995.2010.02434.x
47. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: A double-blind, randomized, placebo-controlled trial. Clin Exp Allergy. 2003;33:1076-82. http://dx.doi.org/10.1046/j.1365-2222. 2003.01735.x
48. Potter PC, Baker S, Fenemore B, Nurse B. Clinical and cytokine responses to house dust mite sublingual immunotherapy. Ann Allergy Asthma Immunol. 2015;114: 327-34. http://dx.doi.org/10.1016/j.anai.2014.12.015
49. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immuno-therapy: Mode of action and its relationship with the safety profile. Allergy. 2012;67:302-11. http://dx.doi.org/10.1111/j. 1398-9995.2011.02761.x
50. Pesek RD, Lockey RF. Treatment of Hymenoptera venom allergy: An update. Curr Opin Allergy Clin Immunol. 2014;14:340-6. http://dx.doi.org/10.1097/ACI.0000000000 000073
51. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: A meta-analysis. Clin Ther. 2000;22:351-8. http://dx.doi.org/10.1016/S0149-2918(00)80039-9
52. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838. http://dx.doi.org/10.1002/ 14651858.CD008838.pub2
53. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Risk stratification of systemic allergic reactions during Hymenoptera venom immunotherapy buildup phase. J Dtsch Dermatol Ges. 2014;12:244-55. http://dx.doi.org/10.1111/ddg.12261
54. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428-33. http://dx.doi.org/10.1016/j.jaci. 2012.10.041
55. Sánchez J, Páez B, Macías A, Olmos C, de Falco A. Atopic dermatitis guideline. Position paper from the Latin American Society of Allergy, Asthma and Immunology. Rev Alerg Mex. 2014;61:178-211.
56. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132:110-7. http://dx.doi.org/10.1016/j.jaci.2013.02.044
57. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: A pilot study. Clin Exp Allergy. 2007;37:1277-85. http://dx.doi.org/10.1111/j.1365-2222.2007.02783.x
58. Einarsson R, Dreborg S, Hammarström L, Löfkvist T, Smith CI, Svensson G. Monitoring of mite Dermato-phagoides farinae allergen-specific IgG and IgG subclass distribution in patients on immunotherapy. Allergy. 1992;47: 76-82. http://dx.doi.org/10.1111/j.1398-9995.1992.tb05092.x
59. Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: A multi-centre, randomized, dose-response study. Allergy. 2006;61:202-5. http://dx.doi.org/10.1111/j.1398-9995. 2006.00974.x
60. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440-6. http://dx.doi.org/10.1111/j.1365-2222.1992.tb00145.x
61. Novak N, Bieber T, Hoffmann M, Fölster-Holst R, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polym-erized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130:925-31.e4. http://dx.doi.org/10.1016/j.jaci.2012.08.004
62. Sánchez-Caraballo JM, Cardona-Villa R. Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: Randomized controlled trial. ISRN Allergy. 2012;2012:183983. http://dx.doi.org/10.5402/2012/183983
63. Cardona R, López E, Beltrán J, Sánchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2012;42:90-5. http://dx.doi.org/10.1016/j.aller.2012.07.005
64. Noon L, Cantab BC, Eng FR. Prophylactic inoculation against hay fever. Lancet. 1911;177:1572-3. http://dx.doi.org/10.1016/S0140-6736(00)78276-6
65. Calderón MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936. http://dx.doi.org/10.1002/14651858.CD001936.pub2
66. Cox L, Calderón MA. Subcutaneous specific immuno-therapy for seasonal allergic rhinitis: A review of treatment practices in the US and Europe. Curr Med Res Opin. 2010;26:2723-33. http://dx.doi.org/10.1185/03007995.2010.528647
67. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immu-notherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol. 2010;126:969-75. http://dx. doi.org/10.1016/j.jaci.2010.08.030
68. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011;127(1Suppl.):S1-55. http://dx.doi.org/10.1016/j.jaci.2010.09.034
69. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol. 2003;111:437-48. http://dx.doi.org/10.1067/mai.2003.129
70. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol. 2007;120(3Suppl.):S25-85. http://dx.doi.org/10.1016/j.jaci.2007.06.019
71. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immu-notherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. J Allergy Clin Immunol. 2012;130:1097-107.e2. http://dx.doi.org/10.1016/j.jaci.2012. 08.012
72. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131:1361-6. http://dx.doi.org/10.1016/j.jaci.2013.02.013
73. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: Which is more effective? J Allergy Clin Immunol Pract. 2014;2:144-9. http://dx.doi.org/10.1016/j.jaip.2013.11.018
74. Sánchez J. Adherence to allergen immunotherapy im-proves when patients choose the route of administration: Subcutaneous or sublingual. Allergol Immunopathol (Madr). 2015;43:436-41. http://dx.doi.org/10.1016/j.aller.2014.04.011
75. World Health Organization. About chronic respiratory diseases. Fecha de consulta: 1 de febrero 2015. Disponible en: http:\\www.who.int/respiratory/about_topic/en/index.html
76. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: A review. Allergy. 2012;67:1087-105. http://dx.doi.org/10.1111/j.1398-9995.2012.02861.x
77. Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immu-notherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17:1-322. http://dx.doi.org/10.3310/hta17270
78. Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol. 2008;101:316-24. http://dx.doi.org/10.1016/S1081-1206(10) 60498-X
79. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immu-notherapy: Reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131:1084-91. http://dx.doi.org/10.1016/j.jaci.2012.12.662
80. Dennis R, Caraballo L, García E, Caballero A, Aristizábal G, Córdoba H, et al. Asthma and other allergic conditions in Colombia: A study in 6 cities. Ann Allergy Asthma Immunol. 2004;93:568-74. http://dx.doi.org/10.1016/S1081-1206(10)61265-3
81. Caraballo L, Puerta L, Fernández-Caldas E, Lockey RF, Martínez B. Sensitization to mite allergens and acute asthma in a tropical environment. J Investig Allergol Clin Immunol. 1998;8:281-4.
82. López-Piedrahita E, Sánchez-Caraballo JM, Ramírez-Girado RH, Cardona-Villa R. Effectiveness of allergen immunotherapy in patients with vernal keratoconjuctivitis. Rev Alerg Mex. 2013;60:11-6.


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Revista Biomédica -  https://doi.org/10.7705/issn.0120-4157
ISSN 0120-4157

Instituto Nacional de Salud
INSTITUTO NACIONAL DE SALUD
Avenida Calle 26 No. 51-20
Apartado aéreo 80334 y 80080
Bogotá, D.C., Colombia, S.A.
Teléfono: 05712207700 Ext. 1386
Correo electrónico: biomedica@ins.gov.co